Zelluläre und molekulare Wirkmechanismen von Crataegus-Extrakt: Grundlage für die Therapie kardiovaskulärer Erkrankungen

Brixius, Klara; Willms, Sonja; Schwinger, Robert H. G.

doi:10.1002/pauz.200400104

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is pre-clinical evidence that WS 1442 may have a beneficial effect on human lipid metabolism [ 9 ]. For example, an in vitro experiment using human Hep-G2 cells showed that WS 1442 causes a dose-dependent inhibition of apolipoprotein-B secretion and thereby decreases the formation of oxygenated low-density lipoprotein (LDL), from which a prophylactic effect against atherosclerosis may be expected [ 33 , 34 ].…”

Section: Pharmacology and Nonclinical Data Mode Of Actionmentioning

confidence: 99%

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

Holubarsch

Colucci

Eha

2017

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

Preparations from Crataegus (hawthorn) have a long history in the treatment of heart failure. WS 1442 is a dry extract from hawthorn leaves with flowers (4–6.6:1), extraction solvent of ethanol 45% (w/w), adjusted to 17.3–20.1% of oligomeric procyanidins. Nonclinical studies show that WS 1442 has positive inotropic and antiarrhythmic properties and protects the myocardium from ischemic damage, reperfusion injury, and hypertension-related hypertrophy, improves endothelial functions such as NO synthesis, and delays endothelial senescence. Randomized, controlled trials in patients with heart failure have demonstrated that the herbal medicinal product increases functional capacity, alleviates disabling symptoms, and improves health-related quality of life, all of which have become important targets of heart failure therapy according to current disease management guidelines. Clinical trials (including a 2-year mortality study with polypharmacy and > 1300 patients exposed) and post-marketing surveillance studies have shown that WS 1442 has a very favorable safety profile both as monotherapy and as add-on therapy, where no drug interactions have been observed. No specific adverse reactions to WS 1442 are known to date. WS 1442 may thus help to close the therapeutic gap between systolic and diastolic heart failure for which evidence of efficacy for other cardioactive drugs is sparse. Scientific evidence shows that WS 1442 is safe and has a beneficial effect in patients with heart failure corresponding to New York Heart Association classes II or III. The benefit-risk assessment for WS 1442 is therefore positive.

show abstract

Section: Pharmacology and Nonclinical Data Mode Of Actionmentioning

confidence: 99%